GlassScriptPhysician profile
Ashley G Bruce
NPI 1881222073
$4,343.40
in general payments reported to CMS, 2019-2025
25 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $326 · 2024: $2,016 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,343.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $649.69 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $451.25 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $437.75 | 2023-2025 | |
| Lilly USA, LLC | $392.86 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $364.82 | 2023-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $249.69 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.79 | 2023-2025 | Jardiance, Ofev, Spiriva Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.46 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Novo Nordisk INC | $206.44 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Sumitomo Pharma America, INC. | $185.01 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $166.59 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $148.37 | 2023-2025 | |
| Exact Sciences Corporation | $117.14 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $94.03 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $84.33 | 2023-2024 | Spravato, Xarelto |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $76.71 | 2024 | Freestyle Libre 3 |
| Eisai INC. | $63.17 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $52.64 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi-Aventis U.S. LLC | $43.88 | 2023-2025 | |
| Dexcom, INC. | $28.93 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $18.97 | 2025 | |
| Antares Pharma, INC. | $18.81 | 2024 | Xyosted |
| Otsuka America Pharmaceutical, INC. | $16.69 | 2025 | Rexulti |
| Ironwood Pharmaceuticals, INC | $16.04 | 2024 | |
| Idorsia Pharmaceuticals US INC | $13.34 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.